Management of Deep Vein Thrombosis in the Third Trimester of Pregnancy
For a pregnant woman with acute DVT in the third trimester, initiate therapeutic anticoagulation with low-molecular-weight heparin (LMWH) immediately, which should be continued throughout pregnancy and for at least 3 months total duration, extending through 6 weeks postpartum. 1
Immediate Treatment Approach
Anticoagulation Selection
- LMWH is strongly recommended over unfractionated heparin (UFH) for acute VTE treatment in pregnancy 1
- LMWH offers superior safety profile, more predictable pharmacokinetics, and allows for outpatient management in most cases
- Either once-daily or twice-daily dosing regimens are acceptable 1
Dosing and Monitoring
- Routine anti-Factor Xa monitoring is NOT recommended for dose adjustment 1
- Anti-Xa monitoring may be considered only in special circumstances: renal insufficiency, extremes of body weight, antithrombin deficiency, or concerns about altered drug clearance 2
- Weight-based therapeutic dosing should be used (typically enoxaparin 1 mg/kg twice daily or 1.5 mg/kg once daily)
Setting of Care
Low-risk acute DVT can be managed as an outpatient rather than requiring hospital admission 1
However, hospitalization should be considered for:
- Pulmonary embolism (vs isolated DVT)
- Extensive or limb-threatening thrombosis
- Severe pain requiring parenteral analgesia
- Vital sign abnormalities
- Maternal comorbidities limiting tolerance of recurrence or increasing bleeding risk 2
Advanced Interventions
Catheter-directed thrombolysis is NOT recommended as routine addition to anticoagulation for lower-extremity DVT in pregnancy 1
This recommendation applies to standard DVT cases. While one small study 3 showed promising results with thrombus removal strategies, the ASH guidelines suggest against routine use due to low certainty evidence. Reserve interventional approaches for truly limb-threatening situations requiring multidisciplinary consultation.
Delivery Planning in Third Trimester
Scheduled delivery with prior discontinuation of therapeutic LMWH is recommended 1
Practical Delivery Management:
- Discontinue LMWH when labor begins or 24 hours before scheduled induction/cesarean section
- This allows adequate time for anticoagulation effect to diminish, reducing neuraxial anesthesia complications and bleeding risk
- Coordinate closely between obstetrics, hematology, and anesthesia teams
- Resume anticoagulation 6-12 hours after vaginal delivery or 12-24 hours after cesarean section (if no bleeding complications)
Critical Timing Consideration:
In the third trimester, the proximity to delivery creates unique challenges. If DVT occurs very close to term, the risk-benefit of continuing full anticoagulation through spontaneous labor versus planned delivery must be carefully weighed 4, 5.
Duration of Anticoagulation
Continue anticoagulation for minimum 3 months total AND through at least 6 weeks postpartum 6, 7
- If DVT diagnosed in third trimester, this means continuing well into postpartum period
- Postpartum period carries 30-60 fold increased VTE risk compared to non-pregnant state 6
Follow-Up Care
Initial Follow-Up:
- See patient within 1 week of diagnosis to assess for:
- Signs of progression or recurrence
- Medication adherence
- Complications (heparin-induced thrombocytopenia, skin reactions)
- Proper injection technique 2
Ongoing Monitoring:
The prescribing provider should be clearly identified. This may be:
- Obstetrician (for straightforward cases)
- Maternal-Fetal Medicine specialist
- Hematologist/thrombosis expert (for complex cases, recurrence, bleeding complications, or cutaneous heparin allergies) 2
Important Caveats
Avoid These Pitfalls:
- Do NOT use warfarin or direct oral anticoagulants (DOACs) during pregnancy - warfarin is teratogenic in first trimester and increases fetal intracranial bleeding risk in third trimester 4
- Do NOT withhold treatment while awaiting specialist consultation - maternal mortality risk outweighs other concerns
- Do NOT assume normal pregnancy symptoms - leg edema and dyspnea overlap with DVT/PE symptoms, requiring low threshold for diagnostic evaluation 8, 9
Postpartum Transition:
After delivery and completion of immediate postpartum period, anticoagulation can be transitioned to warfarin or continued LMWH based on patient preference and breastfeeding plans. UFH, LMWH, and warfarin are all safe during breastfeeding 1.
The third trimester presentation requires particularly careful coordination of anticoagulation management with delivery timing to optimize both maternal safety from thrombosis and minimize bleeding complications during delivery.